Publications

The principle investigators of CRC TRR 221 have published the following project-specific publications:

Siegmund D, Ehrenschwender M, Wajant H. TNFR2 unlocks a RIPK1 kinase activity-dependent mode of proinflammatory TNFR1 signaling. Cell Death Dis. 2018 Sep 11;9(9):921. doi: 10.1038/s41419-018-0973-3.

Bittner, S. et al. (2022) ‘Biosensors for inflammation as a strategy to engineer regulatory T cells for cell therapy’, Proceedings of the National Academy of Sciences, 119(40), p. e2208436119. Available at: https://doi.org/10.1073/pnas.2208436119.

Bencurova, E. et al. (2022) ‘Nanocellulose Composites as Smart Devices With Chassis, Light-Directed DNA Storage, Engineered Electronic Properties, and Chip Integration’, Frontiers in Bioengineering and Biotechnology, 10, p. 869111. Available at: https://doi.org/10.3389/fbioe.2022.869111.

Lischer C, Eberhardt M, Flamann C, Berges J, Güse E, Wessely A, Weich A, Retzlaff J, Dörrie J, Schaft N, Wiesinger M, März J, Schuler-Thurner B, Knorr H, Gupta S, Singh KP, Schuler G, Heppt MV, Koch EAT, van Kleef ND, Freen-van Heeren JJ, Turksma AW, Wolkenhauer O, HohbergerB, Berking C, Bruns H, Vera J. Gene network-based and ensemble modeling-based selection of tumor-associated antigens with a predicted low risk of tissue damage for targeted immunotherapy. J Immunother Cancer. 2024 May 9;12(5):e008104.

Biedermann A, Patra-Kneuer M, Mougiakakos D, Büttner-Herold M, Mangelberger-Eberl D, Berges J, Kellner C, Altmeyer S, Bittenbring JT, Augsberger C, Ilieva-Babinsky K, Haskamp S, Beier F, Lischer C, Vera J, Lührmann A, Bertz S, Völkl S, Jacobs B, Steidl S, Mackensen A, Bruns H. Blockade of the CD47/SIRPα checkpoint axis potentiates the macrophage-mediated anti-tumor efficacy of tafasitamab. Haematologica. 2024 Jun 27. doi: 10.3324/haematol.2023.284795.